Advanced non-small cell lung cancer
Conditions
Interventions
Case series:None
Sponsors
Ningbo Traditional Chinese Medicine Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Visit on June 1, 2022 to December 31, 2023; (2) Age = 18 years old; (3) Locally advanced, recurrent, or metastatic non-small cell lung cancer confirmed by histology or cytology as inoperable; Indications for the use of bevacizumab according to clinical diagnosis and treatment conventions; (4) ECOG score 0-1 points; (5) Accept a treatment regimen containing bevacizumab in combination with chemotherapy, radiation therapy, immunotherapy, targeted therapy, or traditional Chinese medicine treatment.
Exclusion criteria
Exclusion criteria: (1) Merge patients with other malignant tumors; (2) Individuals who are allergic to bevacizumab and its excipients; (3) Individuals with severe damage to the liver, kidneys, hematopoiesis, and cardiovascular system; (4) Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival;Objective relief rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Types of adverse reactions;Adverse reaction incidence rate;Short axis of lymph nodes;Lesion metastasis; | — |
Countries
China
Contacts
Public ContactTingsu ZHANG
Ningbo Traditional Chinese Medicine Hospital
Outcome results
None listed